Skip to main content
. 2020 Jun 22;3(6):e205860. doi: 10.1001/jamanetworkopen.2020.5860

Table 3. Estimates of Effect of Exposure to Benzodiazepines or Benzodiazepine-like Hypnotic Drugs.

Exposure Relative risk (95% CI)
Crude analysis Adjusted for baseline confoundersa Adjusted for baseline and time varying confoundersb
Gestational age, d
Never 0 [Reference] 0 [Reference] 0 [Reference]
Ever −2.5 (−3.4 to −1.6) −2.3 (−3.4 to −1.3) −2.1 (−3.3 to −0.9)
Timing
Unexposed 0 [Reference] 0 [Reference] 0 [Reference]
Early 0.1 (−1.1 to 1.2) 0.4 (−0.8 to 1.6) 0.4 (−1.0 to 1.7)
Mid −2.0 (−3.6 to −0.3) −2.3 (−4.6 to −0.1) −1.8 (−4.5 to 1.0)
Late −3.7 (−5.4 to −2.0) −3.4 (−5.7 to −1.0) −3.1 (−5.7 to −0.5)
Duration, 4-wk inteval
0 0 [Reference] 0 [Reference] 0 [Reference]
1 −2.5 (−3.6 to −1.4) −2.5 (−3.8 to −1.1) −2.6 (−4.0 to −1.1)
2 −2.0 (−4.3 to 0.3) −1.5 (−4.5 to 1.4) −0.7 (−3.9 to 2.4)
≥3 −2.8 (−4.7 to −1.0) −2.5 (−4.4 to −0.5) −1.8 (−4.2 to 0.6)
Preterm delivery
Never 1 [Reference] 1 [Reference] 1 [Reference]
Ever 1.55 (1.17 to 2.06) 1.45 (1.08 to 1.94) 1.41 (1.03 to 1.94)
Timing
Unexposed 1 [Reference] 1 [Reference] 1 [Reference]
Early 0.80 (0.50 to 1.29) 0.71 (0.43 to 1.18) 0.64 (0.36 to 1.12)
Mid 1.10 (0.62 to 1.94) 1.18 (0.66 to 2.11) 1.33 (0.69 to 2.55)
Late 2.45 (1.55 to 3.86) 2.31 (1.38 to 3.86) 2.17 (1.23 to 3.83)
Duration, 4-wk inteval
0 1 [Reference] 1 [Reference] 1 [Reference]
1 1.56 (1.09 to 2.22) 1.50 (1.05 to 2.14) 1.49 (1.03 to 2.16)
2 1.91 (0.98 to 3.71) 1.70 (0.87 to 3.36) 1.50 (0.73 to 3.09)
≥3 1.28 (0.65 to 2.51) 1.13 (0.56 to 2.26) 1.14 (0.51 to 2.57)
Birth weight, g
Never 0 [Reference] 0 [Reference] 0 [Reference]
Ever −106.2 (−147.0 to −65.4) −78.5 (−123.0 to −34.0) −79.3 (−126.7 to −31.9)
Timing
Unexposed 0 [Reference] 0 [Reference] 0 [Reference]
Early −25.5 (−79.8 to 28.8) 27.1 (−26.6 to 80.8) 25.8 (−34.2 to 85.8)
Mid −109.1 (−186.1 to −32.1) −107.8 (−198.7 to −16.9) −82.2 (−190.8 to 26.4)
Late −97.5 (−174.7 to −20.3) −116.7 (−208.4 to −25.0) −107.2 (−211.1 to −3.3)
Duration, 4-wk inteval
0 0 [Reference] 0 [Reference] 0 [Reference]
1 −84.8 (−135.6 to −34.0) −63.7 (−120.9 to −6.5) −81.7 (−143.0 to −20.4)
2 −140.9 (−247.5 to −34.3) −92.2 (−206.3 to 21.9) −91.3 (−211.8 to 29.2)
≥3 −146.7 (−234.1 to −59.3) −113.8 (−197.9 to −29.7) −41.5 (−154.4 to 71.4)
Birth weight relative to gestational age and sex, z score
Never 0 [Reference] 0 [Reference] 0 [Reference]
Ever −0.08 (−0.16 to 0.00) −0.04 (−0.12 to 0.04) −0.04 (−0.12 to 0.04)
Timing
Unexposed 0 [Reference] 0 [Reference] 0 [Reference]
Early −0.08 (−0.20 to 0.04) 0.02 (−0.08 to 0.12) 0.01 (−0.09 to 0.11)
Mid −0.12 (−0.28 to 0.04) −0.10 (−0.24 to 0.04) −0.05 (−0.21 to 0.11)
Late 0.02 (−0.14 to 0.18) −0.05 (−0.19 to 0.09) −0.06 (−0.22 to 0.10)
Duration, 4-wk inteval
0 0 [Reference] 0 [Reference] 0 [Reference]
1 −0.03 (−0.15 to 0.09) 0.00 (−0.10 to 0.10) −0.03 (−0.13 to 0.07)
2 −0.23 (−0.45 to −0.01) −0.10 (−0.26 to 0.06) −0.14 (−0.30 to 0.02)
≥3 −0.14 (−0.34 to 0.06) −0.14 (−0.3 to 0.02) −0.01 (−0.21 to 0.19)
Small for gestational age
Never 1 [Reference] 1 [Reference] 1 [Reference]
Ever 1.24 (0.93 to 1.66) 1.11 (0.83 to 1.48) 0.96 (0.69 to 1.33)
Timing
Unexposed 1 [Reference] 1 [Reference] 1 [Reference]
Early 1.15 (0.78 to 1.70) 0.93 (0.63 to 1.37) 0.87 (0.57 to 1.32)
Mid 1.39 (0.83 to 2.30) 1.35 (0.81 to 2.24) 0.98 (0.56 to 1.73)
Late 1.09 (0.63 to 1.88) 1.23 (0.74 to 2.04) 1.26 (0.69 to 2.33)
Duration, 4-wk inteval
0 1 [Reference] 1 [Reference] 1 [Reference]
1 1.01 (0.68 to 1.51) 0.92 (0.62 to 1.37) 0.91 (0.6 to 1.38)
2 1.17 (0.54 to 2.55) 1.02 (0.46 to 2.27) 1.03 (0.45 to 2.39)
≥3 1.97 (1.22 to 3.19) 1.05 (0.65 to 1.71) 1.02 (0.54 to 1.91)
Head circumference, cm
Never 0 [Reference] 0 [Reference] 0 [Reference]
Ever −0.2 (−0.3 to −0.1) −0.1 (−0.3 to 0.0) −0.1 (−0.3 to 0.1)
Timing
Unexposed 0 [Reference] 0 [Reference] 0 [Reference]
Early −0.1 (−0.2 to 0.1) 0.1 (−0.1 to 0.3) 0.1 (−0.1 to 0.3)
Mid −0.1 (−0.2 to 0.1) 0.0 (−0.4 to 0.3) 0.1 (−0.3 to 0.6)
Late −0.4 (0.3 to −1.0) −0.4 (−0.7 to −0.1) −0.4 (−0.7 to −0.1)
Duration, 4-wk inteval
0 0 [Reference] 0 [Reference] 0 [Reference]
1 −0.2 (−0.3 to 0) −0.1 (−0.3 to 0.1) −0.1 (−0.3 to 0.1)
2 −0.2 (−0.5 to 0.2) 0.0 (−0.5 to 0.5) 0.0 (−0.5 to 0.4)
≥3 −0.3 (−0.6 to −0.1) −0.2 (−0.4 to 0.1) 0.1 (−0.3 to 0.4)
Apgar Score <7 at 5 minc
Never 1 [Reference] 1 [Reference] 1 [Reference]
Ever 1.09 (0.52 to 2.28) 1.08 (0.51 to 2.29) 1.28 (0.59 to 2.79)
Timing
Unexposed 1 [Reference] 1 [Reference] 1 [Reference]
Early 0.76 (0.23 to 2.48) 0.71 (0.20 to 2.58) 0.59 (0.15 to 2.28)
Mid 0.36 (0.04 to 2.91) 0.37 (0.04 to 3.86) 0.44 (0.03 to 5.57)
Late 2.01 (0.61 to 6.66) 2.06 (0.54 to 7.84) 2.90 (0.68 to 12.39)
Respiratory distress
Never 1 [Reference] 1 [Reference] 1 [Reference]
Ever 0.96 (0.36 to 2.54) 0.94 (0.35 to 2.51) 0.61 (0.21 to 1.73)
Timing
Unexposed 1 [Reference] 1 [Reference] 1 [Reference]
Early 0.89 (0.25 to 3.11) 0.90 (0.36 to 2.25) 0.69 (0.28 to 1.73)
Mid 2.13 (0.56 to 8.13) 2.11 (0.71 to 6.28) 1.48 (0.57 to 3.80)
Late 1.02 (0.21 to 5.06) 0.98 (0.18 to 5.41) 1.01 (0.26 to 3.94)
Duration, 4-wk inteval
0 1 [Reference] 1 [Reference] 1 [Reference]
1 0.37 (0.05 to 2.64) 0.37 (0.05 to 2.62) 0.20 (0.03 to 1.45)
2 3.31 (0.84 to 13.08) 3.31 (0.80 to 13.71) 1.77 (0.42 to 7.50)
≥3 1.11 (0.16 to 7.84) 1.04 (0.14 to 7.65) 1.04 (0.14 to 7.68)
a

Baseline covariates: body mass index before conception, smoking, illicit drug use, alcohol intake, planned pregnancy, income, ongoing or completed education, adverse life events, sleeping and mental health issues, anxiety, and lifetime history of major depression.

b

Time-varying covariates: maternal symptoms of depression and anxiety during pregnancy, comedication use during pregnancy (ie, nonsteroidal anti-inflammatory drugs, opioids, paracetamol, antidepressants, antipsychotics, and antiepileptics), and fever during pregnancy.

c

For the outcome Apgar score less than 7 at 5 minutes, duration analysis is omitted as there were no events in some exposure groups.